)
)
)
Roundtable: Poland - Dapagliflozin and the Future of Pharmaceutical Patent Litigation in Poland
The revocation of AstraZeneca's dapagliflozin patent by the Polish Patent Office in February 2026 culminated a protracted revocation proceeding and brought renewed attention to key questions surrounding pharmaceutical patent validity and generic market entry. This roundtable reviews the lessons emerging from the dispute and explores their implications for originators and generic manufacturers, providing practical insights into lifecycle management, validity challenges and litigation strategy, both in Poland and further afield.